These findings collectively suggest that HepLPCs primarily suppress HCC proliferation by inducing mitochondrial dysfunction, which in turn leads to the combined inhibition of the Notch1 and STAT3 signaling pathways. The gene discussed is NOTCH1; the disease is hepatocellular carcinoma.